{
    "id": 105,
    "premise": "none",
    "hypothesis": "HER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
    "label": "entailment",
    "explanation": "Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "HER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
        "history explanation": [
            "0 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "1 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "2 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "3 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "4 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "5 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "6 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "7 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "8 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "9 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "10 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_105_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitoryEffect :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 entity\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain y) \u2227 InhibitoryEffect z \u2227 \u00acHave e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Mutation z \u2227 In z (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Mutation x \u2227 Located y \u2227 In x (TyrosineKinaseDomain y)\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 In (Mutation z) (IntracellularKinaseDomain z)\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer that HER2 V777L may cause resistance to trastuzumab. *)\\n  then have \"\u2203e x y. HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* From explanatory sentence 1, we know that trastuzumab binds to the HER2 extracellular domain. *)\\n  (* We can also infer that trastuzumab binds to the extracellular kinase domain. *)\\n  then have \"\u2203e1 e2 x y z. HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 In (Mutation z) (IntracellularKinaseDomain z)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.786887645721436, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (e1, x) :: event \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_1\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  NoInhibitoryEffect :: \"entity\"\\n  ActivatingMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 HER2ExtracellularDomain \u2227 Have e2 \u2227 Agent e2 x \u2227 Patient e2 NoInhibitoryEffect \u2227 ActivatingMutation y \u2227 In y IntracellularKinaseDomain\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Located y \u2227 In x TyrosineKinaseDomain\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, z) \u2227 Patient(e2, Trastuzumab) \u2227 ExtracellularKinaseDomain(z) \u2227 In(x, IntracellularKinaseDomain)\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3, we can infer resistance to trastuzumab. *)\\n  then have \"\u2203e x y. HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* We also know from explanatory sentence 1 that trastuzumab binds to the HER2 extracellular domain, which is different from the intracellular kinase domain where the mutation is located. *)\\n  then have \"\u2203e1 e2 x y z. HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 Trastuzumab \u2227 In x IntracellularKinaseDomain\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.396771430969238, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (e1, x) :: event \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitoryEffect :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain y) \u2227 InhibitoryEffect z \u2227 \u00acHave e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Mutation z \u2227 In z (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Mutation x \u2227 Located y \u2227 In x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, y) \u2227 Patient(e2, HER2ExtracellularDomain(z)) \u2227 In x z \u2227 In z (IntracellularKinaseDomain z)\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x \u2227 Mutation x \u2227 Located y \u2227 In x y\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* We can infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  then obtain e y where \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* From explanatory sentence 1, we know that trastuzumab binds to the HER2 extracellular domain. *)\\n  (* However, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\n  (* This information is not directly relevant to the hypothesis. *)\\n  (* Therefore, we can ignore this information and focus on the relevant information about HER2 V777L. *)\\n  then obtain e1 e2 z where \"HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 In z (IntracellularKinaseDomain z)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.757782459259033, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent e2 :: entity \\\\<Rightarrow> bool\\nOperand:   Trastuzumab :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_3\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  NoInhibitoryEffect :: \"entity \u21d2 bool\"\\n  ActivatingMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 entity\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain x) \u2227 Have e2 \u2227 Agent e2 x \u2227 Patient e2 x \u2227 NoInhibitoryEffect x \u2227 ActivatingMutation y \u2227 In y (IntracellularKinaseDomain y)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 LocatedIn x (TyrosineKinaseDomain y)\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 Trastuzumab \u2227 Patient e2 (ExtracellularKinaseDomain Trastuzumab) \u2227 In x (IntracellularKinaseDomain x)\"\\nproof -\\n  (* From the premise, we know that HER2 V777L x. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  \\n  (* We have the logical relation Implies(C, D), which states that if the HER2 V777L mutation is located in the tyrosine kinase domain, then it may cause resistance to antibody therapy. *)\\n  (* Using the information from explanatory sentence 2, we can infer that HER2 V777L x is located in the tyrosine kinase domain. *)\\n  from explanation_2 obtain y where \"LocatedIn x (TyrosineKinaseDomain y)\" by auto\\n  \\n  (* We also have the logical relation Implies(A, B), which states that if trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\n  (* Using the information from explanatory sentence 1, we can infer that trastuzumab binds to the HER2 extracellular domain. *)\\n  from explanation_1 obtain e1 e2 z where \"Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain x) \u2227 Have e2 \u2227 Agent e2 x \u2227 Patient e2 x \u2227 NoInhibitoryEffect x \u2227 ActivatingMutation y \u2227 In y (IntracellularKinaseDomain y)\" by auto\\n  \\n  (* Combining the above information, we can conclude that HER2 V777L x may cause resistance to trastuzumab. *)\\n  then have \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 Trastuzumab \u2227 Patient e2 (ExtracellularKinaseDomain Trastuzumab) \u2227 In x (IntracellularKinaseDomain x)\" by auto\\n  \\n  then show ?thesis by auto\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.592226505279541, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (e1, x) :: event \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  InhibitoryEffect :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  ActivatingMutation :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 InhibitoryEffect y \u2227 Have e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 x \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 ActivatingMutation y \u2227 In y (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, y) \u2227 Patient(e2, HER2ExtracellularDomain(z)) \u2227 In(x, z) \u2227 In(y, IntracellularKinaseDomain(z))\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer the hypothesis based on the known information. *)\\n  then obtain e y where \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* We also know that trastuzumab binds to the HER2 extracellular domain, which may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\n  (* This information is from explanatory sentence 1. *)\\n  then obtain e1 e2 z where \"HER2V777L x \u2227 ResistanceToTrastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 x \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 In y (IntracellularKinaseDomain z)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.94646692276001, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (e1, x) :: event \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  InhibitoryEffect :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  ActivatingMutation :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 InhibitoryEffect y \u2227 Have e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 x \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 ActivatingMutation y \u2227 In y (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, y) \u2227 Patient(e2, ExtracellularKinaseDomain(z)) \u2227 In(x, z) \u2227 In(y, IntracellularKinaseDomain(z))\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  then have \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y\" <ATP>\\n  (* We need to show the rest of the hypothesis. *)\\n  (* We can use explanatory sentence 1 to infer the rest of the hypothesis. *)\\n  (* However, the hypothesis contains \"ResistanceToTrastuzumab(y)\" which is not directly provided in the axioms. *)\\n  (* Therefore, we cannot fully prove the hypothesis with the given information. *)\\n  (* The proof is inconclusive due to the missing link between ResistanceToTrastuzumab and the existing axioms. *)\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.024178743362427, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (e1, x) :: event \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  NoInhibitoryEffect :: \"entity \u21d2 bool\"\\n  ActivatingMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 entity\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain x) \u2227 Have e2 \u2227 Agent e2 x \u2227 Patient e2 x \u2227 NoInhibitoryEffect x \u2227 ActivatingMutation y \u2227 In y (IntracellularKinaseDomain y)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 LocatedIn x (TyrosineKinaseDomain y)\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, trastuzumab) \u2227 Patient(e2, ExtracellularKinaseDomain(trastuzumab)) \u2227 In(x, IntracellularKinaseDomain(x))\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  then have \"ResistanceToAntibodyTherapy y\" for y by (rule explanation_3[where e=e and x=x]) <ATP>\\n  (* Now, we need to show the rest of the hypothesis. *)\\n  (* We have the information that trastuzumab binds to the HER2 extracellular domain, which may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\n  (* This information is from explanatory sentence 1. *)\\n  (* We can use this to infer the rest of the hypothesis. *)\\n  then obtain e1 e2 x y z where \"HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, trastuzumab) \u2227 Patient(e2, ExtracellularKinaseDomain(trastuzumab)) \u2227 In(x, IntracellularKinaseDomain(x))\"\\n    by (rule explanation_1[where e1=e1 and e2=e2 and x=x and y=y and z=z]) <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.526057004928589, 'proof tactics': ['Type unification failed: Clash of types \"bool\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  In :: entity \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   Mutation z :: bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitoryEffect :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Located :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain y) \u2227 InhibitoryEffect z \u2227 \u00acHave e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Mutation z \u2227 In z (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Mutation x \u2227 Located y \u2227 In x y \u2227 TyrosineKinaseDomain y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 In (Mutation z) (IntracellularKinaseDomain z)\"\\nproof -\\n  (* From the premise, we know that HER2V777L x. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* We have the logical relation Implies(C, D), which states that HER2 V777L mutation is located in the tyrosine kinase domain implies that HER2 V777L may cause resistance to antibody therapy. *)\\n  (* Using the information from explanatory sentence 2, we can infer that HER2 V777L x is located in the tyrosine kinase domain. *)\\n  from explanation_2 obtain y where \"HER2V777L x \u2227 Mutation x \u2227 Located y \u2227 In x y \u2227 TyrosineKinaseDomain y\" by auto\\n  (* We also have the information from explanatory sentence 3 that HER2 V777L may cause resistance to antibody therapy. *)\\n  from explanation_3 obtain e where \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" by auto\\n  (* Now, we need to show the conclusion based on the given information. *)\\n  then have \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" by auto\\n  (* Additionally, we have the information from explanatory sentence 1 that trastuzumab binds to the HER2 extracellular domain and may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\n  from explanation_1 obtain e1 e2 z where \"Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain z) \u2227 InhibitoryEffect z \u2227 \u00acHave e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Mutation z \u2227 In z (IntracellularKinaseDomain z)\" by auto\\n  (* Combining the information, we can derive the conclusion. *)\\n  then have \"HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 (HER2ExtracellularDomain z) \u2227 In x z \u2227 In (Mutation z) (IntracellularKinaseDomain z)\" by auto\\n  then show ?thesis by auto\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_105_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  HER2ActivatingMutation :: \"entity \u21d2 entity\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Effect :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  MutationIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain y) \u2227 In y z \u2227 \u00acEffect e2 \u2227 Agent e2 x \u2227 \u00acEffect e2 (HER2ActivatingMutation z) \u2227 In z (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 MutationIn x (IntracellularKinaseDomain y)\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, y) \u2227 Patient(e2, HER2ExtracellularDomain(z)) \u2227 In(x, z) \u2227 \u00acEffect(e3) \u2227 Agent(e3, x) \u2227 \u00acEffect(e3, y) \u2227 MutationIn(x, IntracellularKinaseDomain(z))\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer the hypothesis based on the known information about HER2 V777L. *)\\n  then have \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToAntibodyTherapy(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, y) \u2227 Patient(e2, HER2ExtracellularDomain(z)) \u2227 In(x, z) \u2227 \u00acEffect(e3) \u2227 Agent(e3, x) \u2227 \u00acEffect(e3, y) \u2227 MutationIn(x, IntracellularKinaseDomain(z))\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.700641870498657, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<times> _\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Agent :: event \\\\<Rightarrow> entity \\\\<Rightarrow> bool\\nOperand:   (e1, x) :: event \\\\<times> entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_105_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  HER2ActivatingMutation :: \"entity \u21d2 entity\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Negation :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  InMutation :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain y) \u2227 Inhibit e2 \u2227 Negation e2 \u2227 Agent e2 x \u2227 Patient e2 (HER2ActivatingMutation z) \u2227 In x z \u2227 InMutation z (IntracellularKinaseDomain z)\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L(x) \u2227 ResistanceToTrastuzumab(y) \u2227 Cause(e1) \u2227 Agent(e1, x) \u2227 Patient(e1, y) \u2227 Bind(e2) \u2227 Agent(e2, y) \u2227 Patient(e2, ExtracellularKinaseDomain(z)) \u2227 In(x, z) \u2227 InMutation(x, IntracellularKinaseDomain(z))\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  then obtain e y where \"ResistanceToAntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* We also know that trastuzumab binds to the HER2 extracellular domain, which may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\n  (* This information is from explanatory sentence 1. *)\\n  then obtain e1 e2 z where \"Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain z) \u2227 Inhibit e2 \u2227 Negation e2 \u2227 Agent e2 x \u2227 Patient e2 (HER2ActivatingMutation z) \u2227 In x z \u2227 InMutation z (IntracellularKinaseDomain z)\" <ATP>\\n  (* We can combine the obtained information to form the desired conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_105_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2ExtracellularDomain :: \"entity \u21d2 entity\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  NoInhibitoryEffect :: \"entity \u21d2 bool\"\\n  ActivatingMutation :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  ResistanceToAntibodyTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203e1 e2 x y z. Trastuzumab x \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 (HER2ExtracellularDomain x) \u2227 Have e2 \u2227 Agent e2 x \u2227 Patient e2 x \u2227 NoInhibitoryEffect x \u2227 ActivatingMutation y \u2227 In y x \u2227 Cause e2 x\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain *)\\naxiomatization where\\n  explanation_2: \"\u2203x. HER2V777L x \u2227 LocatedIn x (TyrosineKinaseDomain x)\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy *)\\naxiomatization where\\n  explanation_3: \"\u2203e x y. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e x \u2227 Agent e x \u2227 Patient e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n shows \"\u2203e1 e2 x y z. HER2V777L x \u2227 ResistanceToAntibodyTherapy y \u2227 Cause e1 x \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 Trastuzumab \u2227 Patient e2 (HER2ExtracellularDomain Trastuzumab) \u2227 In x (TyrosineKinaseDomain x)\"\\nproof -\\n  (* From the premise, we know that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  from asm have \"HER2V777L x \u2227 LocatedIn x (TyrosineKinaseDomain x)\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy) *)\\n  (* Both C and D are from explanatory sentence 2 and 3. *)\\n  (* We can infer the hypothesis based on the known information. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain\\nB: have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain\\nC: HER2 V777L mutation is located in the tyrosine kinase domain\\nD: HER2 V777L may cause resistance to antibody therapy\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}